KBR, Inc.
KBRKBR, Inc. is cheap for a reason. The P/E sits at the 6th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: annual EPS moved +15.1% against a −18.6% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (70 weeks in) while the P/E sits at the 6th percentile of its own 4-year range. Underneath, the last four quarters read deteriorating — profit −16.7% year on year, and 134% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
KBR, Inc. trades at $37.8, in a downtrend and 70 weeks into that stage. That is −2.6% against its own 200-day average. It sits at 37% of a 52-week range of $30 to $51. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 70 of stage 4. At $37.8 it trades −2.6% versus its 200-day average and sits at 37% of its 52-week range ($30–$51).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +178% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
KBR, Inc. trades at 11.4× P/E, near the bottom of its own range — cheaper only 6% of the time. Its long-run median P/E is 24.7×, measured across 4.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 11.4× is near the bottom of its own range — cheaper only 6% of the time, against a long-run median of 24.7× measured over 4.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +15.1% against a −18.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the −14.9%/yr price move, ~+11.3%/yr came from earnings growth and ~−26.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
KBR, Inc. reads as topping out on its fundamental arc. Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +11.9% at its peak → −2.9% latest) while ROCE still reads 15.1%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.0% | +3.8% | +1.2% | — |
| Profit | +21.1% | — | +63.0% | — |
| EPS | +15.1% | — | +76.0% | — |
| Stock price | −18.6% | −14.9% | −0.2% | +9.4% |
4-Factor Sector Score
43.1/100 — rank 19 of 30 in Engineering & Construction · 56% evidence confidence
KBR, Inc. scores 43.1 out of 100 against the 30 companies it is compared with in Engineering & Construction, ranking 19. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 14.1 + 10.3 + 11.4 + 7.3 = 43.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
KBR, Inc. reported $1.9 B of revenue in the Apr 26 quarter, −5.0% year on year. Over 5 years it has compounded at 1.2% a year. The last full year, FY26, came in at $7.8 B. The last four reported quarters add to $7.7 B.
FY26 revenue came in at $7.8 B (+1.0% on the year), capping 5 years at 1.2% compound. The latest quarter (Apr 26) printed $1.9 B, −5.0% year on year.
Pace check: the last four quarters averaged −2.6% growth against the decade's 1.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −2.9% over the last 4 quarters against +4.3%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
KBR, Inc.'s operating margin is 9.4% in the Apr 26 quarter, −0.5 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 3.1% to 10.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 9.4%, −0.5 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.1%–10.0%, and FY26's 10.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −0.5 pp year on year while gross margin went −0.8 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
KBR, Inc. earned $0.1 B of net profit in the Apr 26 quarter, −16.7% year on year. Full-year FY26 profit was $0.5 B. The 5-year compound rate is 63.0%. That is 5.2% of the quarter's revenue. The same quarter a year earlier earned $0.1 B. 2 of the last 12 reported quarters were loss-making.
Apr 26 profit was $0.1 B, −16.7% year on year. On the full year, FY26 printed $0.5 B (+21.1%), and the 5-year compound rate is 63.0%.
🚨 Why profit moved: revenue contributed −5.0% and the margin −0.5 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −1.2% vs revenue −2.6%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 134% of KBR, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $0.5 B of operating cash against $0.5 B of profit. After $0.0 B of capital spending, $0.5 B was left as free cash.
FY26: operating cash of $0.5 B against reported profit of $0.5 B, leaving free cash of $0.5 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 134% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
KBR, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
KBR, Inc. earns a ROE of 31% in FY26. That is up from a trough of −19% in FY23. Return on invested capital clears the cost of that capital by +4.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 5.9% net margin on 1.18× asset turns.
FY26 ROE is 31%, recovered from a FY23 trough of −19% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 5.9% net margin × 1.18× asset turns × 4.36× balance-sheet leverage ≈ 30.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.2% − 5.7% = a +4.5 pp spread. The 5.7% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
KBR, Inc. paid $0.66 per share over the last four reported quarters, up 10.0% on a year ago. The most recent declaration was $0.17 for Apr 26. Against the current price of $37.8 that is a trailing yield of 1.74%, measured on dividends already paid rather than on a forecast.
KBR, Inc. paid $0.66 per share across the last four reported quarters, most recently $0.17 for Apr 26. That is up 10.0% against the same quarter a year earlier. Against the current price of $37.8 the trailing twelve months work out to 1.74% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
KBR, Inc. carries total debt of $2.8 B against shareholder equity of $1.6 B as of Jul 26, a debt-to-equity of 1.71. On the annual view that ratio went from 1.26 in FY21 to 1.87 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Jul 26: total debt of $2.8 B against shareholder equity of $1.6 B — a debt-to-equity of 1.71. On the annual view, debt-to-equity went from 1.26 (FY21) to 1.87 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
6.7% of KBR, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 6.7% of the float is sold short, and at typical trading volumes it would take about 4.4 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
KBR, Inc.: the Z-score reads 2.51. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.51 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.51.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Argan, Inc.AGX | 69.3/100Favorable setup81% evidence | ASLEEP | 26.6/35 Revenue 14.5% · PAT 61% · OPM change 3 pp 83% evidence | 16.1/25 ROCE 10.5% · OPM 15.6% 76% evidence | 12.3/20 P/E 58.9× · PEG 0.99 65% evidence | 14.3/20 RS sector 24.9% · RS bench 25.1% · 1Y 158.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 16.1 + 12.3 + 14.3 = 69.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Comfort Systems USA, Inc.FIX | 66.8/100Thin evidence · provisional56% evidence | ASLEEP | 23.6/35 Revenue — · PAT — · OPM change 5.6 pp 39% evidence | 20.1/25 ROCE 18.3% · OPM 17% 76% evidence | 9.3/20 P/E 48.8× · PEG — 15% evidence | 13.8/20 RS sector 24.3% · RS bench 25% · 1Y 156.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 20.1 + 9.3 + 13.8 = 66.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3IES Holdings, Inc.IESC | 65.9/100Thin evidence · provisional53% evidence | LEADER | 19.7/35 Revenue — · PAT — · OPM change 1.2 pp 32% evidence | 17.1/25 ROCE 15.8% · OPM 11.2% 76% evidence | 10.2/20 P/E 32.6× · PEG — 15% evidence | 18.9/20 RS sector 36% · RS bench 37.9% · 1Y 119.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 17.1 + 10.2 + 18.9 = 65.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Everus Construction Group, Inc.ECG | 64.6/100Mixed-positive evidence66% evidence | ASLEEP | 22.5/35 Revenue 29.7% · PAT 46.7% · OPM change 1.3 pp 53% evidence | 13.8/25 ROCE 8.4% · OPM 7.5% 57% evidence | 15.2/20 P/E 27.1× · PEG 0.58 65% evidence | 13.1/20 RS sector 10.4% · RS bench 11.9% · 1Y 90.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 13.8 + 15.2 + 13.1 = 64.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Sterling Infrastructure, Inc.STRL | 62.8/100Mixed-positive evidence66% evidence | FADING | 24.3/35 Revenue 36.9% · PAT 32.5% · OPM change 3.7 pp 53% evidence | 15.4/25 ROCE 9.3% · OPM 16.7% 57% evidence | 11.8/20 P/E 36.4× · PEG 1.19 65% evidence | 11.3/20 RS sector 4.4% · RS bench 5.1% · 1Y 78.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 15.4 + 11.8 + 11.3 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Dycom Industries, Inc.DY | 57.5/100Mixed-positive evidence81% evidence | ASLEEP | 22.2/35 Revenue 29.8% · PAT 34.2% · OPM change 0.5 pp 83% evidence | 11.9/25 ROCE 3.8% · OPM 7.3% 76% evidence | 11.1/20 P/E 41.3× · PEG 1.24 65% evidence | 12.3/20 RS sector 1.1% · RS bench 2.9% · 1Y 48.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 11.9 + 11.1 + 12.3 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7EMCOR Group, Inc.EME | 56.8/100Thin evidence · provisional56% evidence | ASLEEP | 19.6/35 Revenue — · PAT — · OPM change 0.5 pp 39% evidence | 16.4/25 ROCE 12.2% · OPM 8.7% 76% evidence | 10.7/20 P/E 25.8× · PEG — 15% evidence | 10.1/20 RS sector -0.3% · RS bench 1.9% · 1Y 32.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 16.4 + 10.7 + 10.1 = 56.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8MYR Group Inc.MYRG | 56.3/100Thin evidence · provisional56% evidence | FADING | 21.9/35 Revenue — · PAT — · OPM change 2.4 pp 39% evidence | 12.6/25 ROCE 7.9% · OPM 6.5% 76% evidence | 9.5/20 P/E 47.5× · PEG — 15% evidence | 12.3/20 RS sector 5.8% · RS bench 6.6% · 1Y 83.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 12.6 + 9.5 + 12.3 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Arcosa, Inc.ACA | 55.2/100Mixed-positive evidence66% evidence | BREAKING OUT | 19.6/35 Revenue 12.1% · PAT 100% · OPM change 0.7 pp 53% evidence | 9.3/25 ROCE 1.1% · OPM 8.2% 57% evidence | 8.5/20 P/E 23.4× · PEG 2.09 65% evidence | 17.8/20 RS sector 12% · RS bench 14.7% · 1Y 51.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 9.3 + 8.5 + 17.8 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Tetra Tech, Inc.TTEK | 55.2/100Thin evidence · provisional56% evidence | TURNING | 19.1/35 Revenue — · PAT — · OPM change 7.8 pp 39% evidence | 13.9/25 ROCE 5.2% · OPM 10.8% 76% evidence | 11.3/20 P/E 17.6× · PEG — 15% evidence | 10.9/20 RS sector -8.7% · RS bench -5.4% · 1Y -5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 13.9 + 11.3 + 10.9 = 55.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Quanta Services, Inc.PWR | 54.8/100Thin evidence · provisional56% evidence | ASLEEP | 19.9/35 Revenue — · PAT — · OPM change 0.5 pp 39% evidence | 11.6/25 ROCE 4.4% · OPM 4.3% 76% evidence | 8.8/20 P/E 82.5× · PEG — 15% evidence | 14.5/20 RS sector 15.7% · RS bench 17.3% · 1Y 79.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 11.6 + 8.8 + 14.5 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Exponent, Inc.EXPO | 51.5/100Thin evidence · provisional56% evidence | TURNING | 17.8/35 Revenue — · PAT — · OPM change -5.6 pp 39% evidence | 15.0/25 ROCE 5% · OPM 24.9% 76% evidence | 10.5/20 P/E 27.3× · PEG — 15% evidence | 8.2/20 RS sector -13.2% · RS bench -10.1% · 1Y -4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 15 + 10.5 + 8.2 = 51.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Tutor Perini CorporationTPC | 49.6/100Thin evidence · provisional51% evidence | ASLEEP | 16.5/35 Revenue 25.6% · PAT — · OPM change -0.9 pp 40% evidence | 8.2/25 ROCE 3.2% · OPM 4.3% 57% evidence | 9.2/20 P/E 52.5× · PEG — 15% evidence | 15.7/20 RS sector 3.6% · RS bench 6% · 1Y 51.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 8.2 + 9.2 + 15.7 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Cadeler A/SCDLR | 48.8/100Mixed-negative evidence66% evidence | ASLEEP | 19.7/35 Revenue 100% · PAT 100% · OPM change -1.2 pp 53% evidence | 7.7/25 ROCE 0.3% · OPM 6.2% 57% evidence | 16.5/20 P/E 6.6× · PEG 0.11 65% evidence | 4.9/20 RS sector -10.4% · RS bench -8.4% · 1Y 8.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 7.7 + 16.5 + 4.9 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Stantec Inc.STN | 47.1/100Mixed-negative evidence66% evidence | BASING | 17.6/35 Revenue 7.6% · PAT 27.6% · OPM change 0.4 pp 53% evidence | 11.4/25 ROCE 3.1% · OPM 8.3% 57% evidence | 13.1/20 P/E 28× · PEG 1.01 65% evidence | 5.0/20 RS sector -32.4% · RS bench -29.6% · 1Y -33.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 11.4 + 13.1 + 5 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16AECOMACM | 44.9/100Mixed-negative evidence66% evidence | BASING | 12.8/35 Revenue -0.4% · PAT 2.6% · OPM change -0.3 pp 53% evidence | 11.4/25 ROCE 4.2% · OPM 6.5% 57% evidence | 15.3/20 P/E 22.1× · PEG 0.73 65% evidence | 5.4/20 RS sector -33.9% · RS bench -30.7% · 1Y -36%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 11.4 + 15.3 + 5.4 = 44.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17APi Group CorporationAPG | 44.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change 0.3 pp 39% evidence | 8.9/25 ROCE 2.5% · OPM 5.2% 76% evidence | 8.7/20 P/E 95.5× · PEG — 15% evidence | 9.1/20 RS sector -9.1% · RS bench -6.8% · 1Y 20.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 8.9 + 8.7 + 9.1 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Fluor CorporationFLR | 43.3/100Thin evidence · provisional56% evidence | TURNING | 11.8/35 Revenue -8.3% · PAT -422.2% · OPM change 0.2 pp 53% evidence | 7.4/25 ROCE 1.8% · OPM 2.5% 57% evidence | 10.8/20 P/E 25.4× · PEG — 15% evidence | 13.3/20 RS sector -2.1% · RS bench 0.5% · 1Y 23%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 7.4 + 10.8 + 13.3 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19KBR, Inc.this pageKBR | 43.1/100Thin evidence · provisional56% evidence | TURNING | 14.1/35 Revenue — · PAT — · OPM change -0.6 pp 39% evidence | 10.3/25 ROCE 3.5% · OPM 9.4% 76% evidence | 11.4/20 P/E 10.9× · PEG — 15% evidence | 7.3/20 RS sector -20% · RS bench -16.8% · 1Y -24.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 10.3 + 11.4 + 7.3 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Granite Construction IncorporatedGVA | 42.8/100Thin evidence · provisional56% evidence | ASLEEP | 18.8/35 Revenue — · PAT — · OPM change 2.3 pp 39% evidence | 9.2/25 ROCE 5.8% · OPM -3.4% 76% evidence | 10.1/20 P/E 34.5× · PEG — 15% evidence | 4.7/20 RS sector -11.4% · RS bench -9.3% · 1Y 15.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 9.2 + 10.1 + 4.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21MasTec, Inc.MTZ | 40.3/100Thin evidence · provisional56% evidence | ASLEEP | 19.8/35 Revenue — · PAT — · OPM change 2.4 pp 39% evidence | 8.4/25 ROCE 3.4% · OPM 3.7% 76% evidence | 9.0/20 P/E 66.4× · PEG — 15% evidence | 3.1/20 RS sector -12% · RS bench -11.1% · 1Y 49.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 8.4 + 9 + 3.1 = 40.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Construction Partners, Inc.ROAD | 39.3/100Mixed-negative evidence66% evidence | BASING | 19.8/35 Revenue 48.7% · PAT 100% · OPM change 0.1 pp 53% evidence | 8.3/25 ROCE 1.5% · OPM 4.9% 57% evidence | 8.2/20 P/E 48.7× · PEG 1.79 65% evidence | 3.0/20 RS sector -20% · RS bench -17.5% · 1Y -4.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 8.3 + 8.2 + 3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Ameresco, Inc.AMRC | 37.0/100Thin evidence · provisional55% evidence | ASLEEP | 14.5/35 Revenue 8.5% · PAT -9.3% · OPM change -1.3 pp 40% evidence | 7.2/25 ROCE 0.3% · OPM 2.6% 57% evidence | 9.9/20 P/E 44× · PEG 1.49 65% evidence | 5.4/20 RS sector -19.2% · RS bench -16.4% · 1Y 38.9%1 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 7.2 + 9.9 + 5.4 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Jacobs Solutions Inc.J | 35.2/100Mixed-negative evidence66% evidence | TURNING | 11.3/35 Revenue 12.7% · PAT -9.3% · OPM change -9.4 pp 53% evidence | 6.8/25 ROCE -1% · OPM -2.2% 57% evidence | 6.9/20 P/E 38.7× · PEG 2.2 65% evidence | 10.2/20 RS sector -9.7% · RS bench -6.3% · 1Y -3.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 6.8 + 6.9 + 10.2 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25TopBuild Corp.BLD | 35.2/100Thin evidence · provisional60% evidence | 11.8/35 Revenue 6.4% · PAT -15.2% · OPM change -2.3 pp 53% evidence | 12.8/25 ROCE 3.6% · OPM 12.1% 57% evidence | 6.3/20 P/E 19.7× · PEG 2.97 65% evidence | 4.3/20 RS sector -30% · RS bench -23.4% · 1Y 2%2 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 11.8 + 12.8 + 6.3 + 4.3 = 35.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Primoris Services CorporationPRIM | 34.3/100Adverse evidence66% evidence | BASING | 13.9/35 Revenue 13.4% · PAT 20.4% · OPM change -2.7 pp 53% evidence | 7.9/25 ROCE 1% · OPM 1.6% 57% evidence | 10.0/20 P/E 31.5× · PEG 1.57 65% evidence | 2.5/20 RS sector -38.4% · RS bench -36.6% · 1Y -18.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 7.9 + 10 + 2.5 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Cardinal Infrastructure Group Inc.CDNL | 50.6/100Thin evidence · provisional22% evidence | BREAKING OUT | 18.6/35 Revenue — · PAT — · OPM change -0.9 pp 15% evidence | 13.5/25 ROCE 5.6% · OPM 8.8% 57% evidence | 8.5/20 P/E 403× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 18.6 + 13.5 + 8.5 + 10 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Ferrovial N.V.FER | 44.7/100Thin evidence · provisional43% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change — 12% evidence | 9.8/25 ROCE 1.3% · OPM — 61% evidence | 8.9/20 P/E 71.4× · PEG — 15% evidence | 8.0/20 RS sector -10.6% · RS bench -8.2% · 1Y 26.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 9.8 + 8.9 + 8 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Legence Corp.LGN | 40.8/100Thin evidence · provisional31% evidence | ASLEEP | 15.7/35 Revenue 44.3% · PAT 13.3% · OPM change -1.1 pp 40% evidence | 6.5/25 ROCE 1.1% · OPM 2.2% 57% evidence | 8.6/20 P/E 192.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 15.7 + 6.5 + 8.6 + 10 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Willdan Group, Inc.WLDN | 37.7/100Thin evidence · provisional50% evidence | BASING | 15.4/35 Revenue — · PAT — · OPM change 0.1 pp 39% evidence | 7.2/25 ROCE 2% · OPM 4.7% 76% evidence | 11.1/20 P/E 21.7× · PEG — 15% evidence | 4.0/20 RS sector -30.8% · RS bench -28.1% · 1Y -32.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 15.4 + 7.2 + 11.1 + 4 = 37.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is KBR, Inc.'s stock price today?
KBR, Inc. trades at $37.8, −18.6% over the past year. The company is valued at $5.0 B. The stock sits at 37% of its 52-week range of $30–$51, −2.6% versus its 200-day average. On the tape, the price is in a downtrend, 70 weeks in. — as of 5 August 2026.
What were KBR, Inc.'s latest quarterly results?
KBR, Inc. reported revenue of $1.9 B and net profit of $0.1 B for the Apr 26 quarter. Revenue fell 5.0% and profit fell 16.7% year on year. Earnings per share were $0.80. The operating margin was 9.4%, 0.5 pp lower than a year earlier. — as of 5 August 2026.
What is KBR, Inc.'s revenue?
KBR, Inc. reported revenue of $1.9 B in the Apr 26 quarter, −5.0% year on year. For the full FY26 fiscal year, revenue was $7.8 B (+1.0%). Over the last 5 years revenue compounded at 1.2% a year. — as of 5 August 2026.
What is KBR, Inc.'s profit?
KBR, Inc. earned $0.1 B of net profit in the Apr 26 quarter, −16.7% year on year. Full-year FY26 profit was $0.5 B. The operating margin ran 9.4% in the latest quarter. — as of 5 August 2026.
What is KBR, Inc.'s market cap?
KBR, Inc.'s market capitalisation is $5.0 B at a stock price of $37.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is KBR, Inc.'s P/E ratio?
KBR, Inc. trades at a P/E of 11.4×, at the 6th percentile of its own 4-year range, against a long-run median of 24.7×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does KBR, Inc. pay a dividend?
Yes — KBR, Inc. declared $0.17 per share for Apr 26, and $0.66 per share across the last four reported quarters. The latest quarter is up 10.0% on the same quarter a year earlier. — as of 5 August 2026.
What is KBR, Inc.'s dividend per share?
KBR, Inc.'s most recently declared dividend is $0.17 per share for Apr 26, giving $0.66 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is KBR, Inc.'s dividend yield?
KBR, Inc.'s trailing dividend yield is 1.74%: $0.66 declared per share across the last four reported quarters, against a share price of $37.8. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is KBR, Inc. overvalued?
On its own history, KBR, Inc. looks cheap against its own history: its P/E of 11.4× has been cheaper only 6% of the time in 4 years (long-run median 24.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.
Is KBR, Inc. growing?
Not right now — KBR, Inc.'s latest numbers are shrinking: latest-quarter revenue −5.0% year on year, profit −16.7%, and the margin −0.5 pp at 9.4%. The 5-year compound rates are 1.2% (revenue) and 63.0% (profit). The earnings engine currently reads: deteriorating — as of 5 August 2026.
How is KBR, Inc. performing?
KBR, Inc. is in a downtrend, 70 weeks in. Its latest quarter's revenue fell 5.0% and profit fell 16.7% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is KBR, Inc. in?
Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +11.9% at its peak → −2.9% latest) while ROCE still reads 15.1%. The read comes from the last 12 quarters of growth (revenue growth −2.9% latest, profit growth −4.9% latest, eps growth +5.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is KBR, Inc. in an uptrend?
No — the price is in a downtrend (week 70 of stage 4), trading −2.6% versus its 200-day average and at 37% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is KBR, Inc. beating the market?
On recent form, yes — KBR, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +178% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will KBR, Inc.'s stock price go up?
This page publishes no price forecast for KBR, Inc. What it measures instead: the stock price is $37.8, the price is in a downtrend 70 weeks in. Its P/E of 11.4× sits at the 6th percentile of its own 4-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against KBR, Inc.?
Somewhat — short interest is 6.7% of KBR, Inc.'s tradable float, about 4.4 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does KBR, Inc. have too much debt?
It carries real leverage — KBR, Inc.'s debt-to-equity is 1.70. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is KBR, Inc.'s capex?
KBR, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.0 B. — as of 5 August 2026.
What is KBR, Inc.'s cash flow?
KBR, Inc. generated $0.5 B of operating cash flow in FY26 and $0.5 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.5 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is KBR, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 134% of KBR, Inc.'s reported profit arrived as operating cash. In FY26, operating cash was $0.5 B against reported profit of $0.5 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is KBR, Inc.?
On the balance sheet, the Z-score reads 2.51 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.
Where is KBR, Inc. in its business cycle?
KBR, Inc.'s FY26 operating margin was 10.0%, against a 5-year band of 3.1%–10.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 9.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the KBR, Inc. story?
The sharpest disagreement: annual EPS moved +15.1% against a −18.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is KBR, Inc. a stock worth studying right now?
This is not investment advice. The machine read: KBR, Inc. is cheap for a reason. The P/E sits at the 6th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.